Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria-Reference-Cited by-同舟云学术

Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

Published:2016 Issue:2 Volume:39 Page:285-288
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Nakayama Hirokazu¹,Usuki Kensuke²,Echizen Hirotoshi³,Ogawa Ryuichi³,Orii Takao¹

Affiliation:

1. Department of Pharmacy, NTT Medical Center Tokyo

2. Department of Hematology, NTT Medical Center Tokyo

3. Department of Pharmacotherapy, Meiji Pharmaceutical University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/39/2/39_b15-00703/_pdf

Reference15 articles.

1. 1) Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol., 25, 1256–1264 (2007).

2. 2) Röth A, Dührsen U. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Eur. J. Haematol., 87, 473–479 (2011).

3. 3) Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol., 33, 1389–1401 (1996).

4. 4) Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med., 350, 552–559 (2004).

5. 5) Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, Mojcik CF, Rother RP. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood, 106, 2559–2565 (2005).

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors;International Journal of Molecular Sciences;2024-08-31

2. Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis;Clinical and Applied Thrombosis/Hemostasis;2024-01

3. Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations;Journal of Blood Medicine;2023-12

4. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis;Advances in Therapy;2023-11-24

5. Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape;Blood Reviews;2023-11